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Adipogenesis and lipogenesis are highly sensitive to the nutritional environment in utero
and in early postnatal life. Omega-3 long chain polyunsaturated fatty acids (LCPUFA) inhibit
adipogenesisandlipogenesisinadultrats,however it is not known whethersupplementing
the maternal diet with omega-3 LCPUFA results in reduced fat deposition in the offspring.
Female Albino Wistar rats were fed either a standard chow (Control, n=1 0 )o rc h o w
designed to provide ∼15mg/kg/day of omega-3 LCPUFA, chieﬂy as docosahexaenoic acid
(DHA), throughout pregnancy and lactation (Omega-3, n=11) and all pups were weaned
onto a commercial rat chow. Blood and tissues were collected from pups at 3 and 6weeks
of age and weights of visceral and subcutaneous fat depots recorded.The expression of
adipogenic and lipogenic genes in the subcutaneous and visceral fat depots were deter-
mined using quantitative real time reverse transcription-PCR. Birth weight and postnatal
growth were not different between groups. At 6weeks of age, total percentage body
fat was signiﬁcantly increased in both male (5.09±0.32% vs. 4.56±0.2%, P<0.04) and
female (5.15±0.37% vs. 3.89±0.36%, P<0.04) offspring of omega-3 dams compared to
controls.The omega-3 LCPUFA content of erythrocyte phospholipids (as a% of total fatty
acids) was higher in omega-3 offspring (6.7±0.2% vs. 5.6±0.2%, P<0.001).There was
no effect of maternal omega-3 LCPUFA supplementation on the expression of adipogenic
or lipogenic genes in the offspring in either the visceral or subcutaneous fat depots. We
have therefore established that an omega-3 rich environment during pregnancy and lac-
tation in a rodent model increases fat accumulation in both male and female offspring,
particularly in subcutaneous depots, but that this effect is not mediated via upregulation
adipogenic/lipogenic gene transcription. These data suggest that maternal n−3 LCPUFA
supplementation during pregnancy/lactation may not be an effective strategy for reducing
fat deposition in the offspring.
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INTRODUCTION
Obesity is a major public health issue in both industrialized
and semi-industrialized nations across the world (World Health
Organisation,2006). Whilst many factors contribute to the devel-
opmentofobesity,thereisnowevidencethattheriskanindividual
has of becoming obese in later life is related to the nutritional
environment they experience before birth and in early infancy
(McMillen and Robinson, 2005). A world-wide series of human
epidemiological and experimental animal studies in both rodents
and large animal models have shown that exposure to an excess
supply of energy during critical periods of fetal and infant devel-
opment is associated with an increased propensity toward excess
accumulation of body fat in later life (Plagemann et al., 1997;
Armitage et al., 2004; McMillen and Robinson, 2005). In the
sheep, exposure to increased glucose concentrations in late fetal
life increases the expression of genes within adipose cells which
are responsible for promoting lipid storage (Muhlhausler et al.,
2007), and this is associated with an increased accumulation of
adipose tissue by the end of the ﬁrst month of life (Muhlhausler
et al., 2006). Similarly, in pigs, fat cells which are exposed to high
glucoselevelsbeforebirthhaveagreaterlipogeniccapacityinpost-
natal life (Kasser et al., 1981). Thus, the nutritional environment
during the period of fat cell development plays an important role
in deﬁning an individual’s propensity for accumulating adipose
tissue,andthereforetheirriskof becomingoverweightorobese.It
has therefore been suggested that increasing the supply of factors
which suppress fat accumulation in early life may be effective in
reducing body fat mass in child and adult hood (Hauner et al.,
2009).
The omega-3 long chain polyunsaturated fatty acids (LCP-
UFA), docosahexaenoic acid (DHA), and eicosapentaenoic acid
(EPA),play an important role in optimal fetal and neonatal devel-
opment. Whilst most studies to date have focused on their role
in neurodevelopment, there has been increasing interest in their
potential metabolic effects as a result of data from in vitro stud-
ies which have shown that both DHA and EPA can inhibit the
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proliferation and differentiation of pre-adipocytes and selectively
inhibit the activity of pro-adipogenic factors (Ailhaud et al.,2006;
Massiera et al., 2006). In addition, omega-3 LCPUFA also act on
mature adipose cells to inhibit the expression of the key lipogenic
mediatorsterol-regulatedbindingprotein1(SREBP-1c),resulting
in a reduced expression of downstream lipogenic genes,including
Fatty Acid Synthase (FAS) and glycerol 3-phosphate dehydroge-
nase (G3PDH) and a reduced accumulation of lipid (Masden
et al., 2005). There is therefore good evidence in adult rodents
that omega-3 LCPUFAs can reduce the accumulation of body fat
by limiting both the hyperplastic and hypertrophic expansion of
adipose depots (Okuno et al., 1997; Raclot et al., 1997; Ruzickova
et al.,2004).
Despite the evidence linking omega-3 LPCUFA with reduced
fat deposition, there have been few studies in either animals or
humans which have determined the effect of supplementing the
maternal diet with omega-3 LCPUFA on fat deposition in the off-
spring.Thefourpublishedhumanstudieswhichhaveinvestigated
this have been relatively small with high attrition rates and have,
perhaps unsurprisingly given these caveats, produced disparate
results (Muhlhausler et al., 2010b). Whilst animal studies have
more consistently reported a reduction in fat mass in offspring
of mothers receiving a diet supplemented with omega-3 LCP-
UFA during pregnancy and/or lactation (Korotkova et al., 2002;
Massiera et al., 2003; Wyrwoll et al., 2006; Ibrahim et al., 2009),
all but one of these studies have also weaned the offspring onto a
highomega-3LCPUFAdiet.Therefore,itremainsunclearwhether
exposure to an increased supply of omega-3 LCPUFA during the
perinatal period alone is associated with reduced fat mass in the
offspring after weaning.
The aim of the current study was to determine the effect of
supplementing the diet of rat dams with omega-3 LCPUFA dur-
ing pregnancy and lactation on postnatal growth,fat mass and the
expressionof adipogenicandlipogenicgenesinthemajorvisceral
andsubcutaneousfatdepotsinoffspringsuppliedwithastandard
rodentchowdietwithnoomega-3LCPUFAsupplementationafter
weaning.
MATERIALS AND METHODS
ANIMALS AND DIETS
This study was approved by the Animal Ethics Committee of
the Institute of Medical and Veterinary Science, Central North-
ern Adelaide Health Services,South Australia. Twenty-one female
and eight male Albino Wistar rats (200–250g) were individually
housed under a 12h light/12h dark cycle at a room temperature
of 25˚C. Female rats were fed ad libitum on a rat chow which
was designed to have a fatty acid composition which was similar
to the standard Australian diet (40% saturates, 40% monounsat-
urates, 20% polyunsaturates; Meyer et al., 2003; Specialty Feeds,
Glen Forrest, WA, Australia) for at least 3weeks prior to mating
in order to ensure that the fatty acid proﬁle of all animals was
comparable prior to the dietary intervention.After 3weeks on the
diet, blood samples were collected to determine fatty acid status.
Femaleratswerethenmatedandrandomlyassignedtoreceivethe
same diet (5% fat, 0.22% n−3 LCPUFA of total fatty acids, Con-
trol,n =10) or a high omega-3 diet (5% fat,1.29% n−3 LCPUFA
of total fatty acids, Omega-3, n =11) throughout pregnancy and
lactation. The high omega-3 diet was designed to provide a dose
of between 6.5 and 9.0mg n−3 LCPUFA/day (∼15mg/kg/day)
which was equivalent to the dose provided to women in the
largest randomized controlled trial of maternal omega-3 supple-
mentation in pregnancy (Makrides et al., 2010). Both diets were
isocaloric and contained 20% protein,59% carbohydrate,and 5%
fat by weight, such that the only signiﬁcant difference between
the diets was in the fatty acid composition, chieﬂy the omega-
3 LCPUFA content. The fatty acid composition of the Control
and Omega-3 diets is shown in Table 1. Food intake was deter-
minedinalldamsevery2daysduringpregnancyandlactation,and
freshfoodprovided.Damswereweighedweeklyduringpregnancy
and lactation.
Dams were allowed to give birth naturally at term and birth
weight and litter size was recorded. All pups remained with their
natural mothers during the suckling period. Offspring from both
the Control and Omega-3 groups were weaned onto the same
commercialratchow(RatandMousecubes,SpecialtyFeeds,Glen
Forrest, WA, Australia) at 21days of age, which ensured that the
only time when pups in the respective treatment groups were
exposed to different fatty acid environments was during the fetal
and suckling periods. The commercial rat feed contained 20%
protein, 59.4% carbohydrate, and 4.8% fat by weight. The EPA
and DHA content of the feed (expressed as a percentage of total
fatty acids) was 0.02 and 0.05% respectively, and no additional
omega-3 LCPUFA were added to the diet. The pups were weighed
every2daysfrombirthtoweaningandonceaweekthereafteruntil
the end of the experiment.
BLOOD SAMPLE AND TISSUE COLLECTION
Blood and tissues were collected in the non-fasting state from
the dam at the end of lactation and one male and one female
pup from each litter at 3weeks (weaning) and 6weeks of age. All
animals were euthanized with an overdose of CO2. Body weight
was recorded immediately before euthanasia in all animals. After
euthanasia, the length of all rats was measured from the tip of
the nose to the base of the tail. The abdominal circumference
was measured at the largest point of the abdomen. Both of these
measurements were carried out by the same investigator using a
ﬂexibletwinewhichwassubsequentlymeasuredtothenearestmil-
limeter using the same ruler. All adipose tissue depots including
Table 1 | Fatty acid composition of the Control and Omega-3 diets
(values expressed as % total fatty acids); both diets contain 5% fat
(v/v).
Fatty acid Standard diet
(1.5% n−3)
High DHA diet
(3.3% n−3)
P value
Total saturates 43.34±0.09 42.76±0.09 <0.05
16:1n−7 2.66±0.008 2.62±0.004 ns
18:1n−9 33.26±0.17 33.21±0.07 ns
18:2n−6 (LA) 11.93±0.058 11.91±0.10 ns
18:3n−3 (ALA) 1.20±0.002 1.21±0.005 ns
20:5n−3 (EPA) 0.14±0.002 0.34±0.005 <0.01
22:2n−6 0.027±0.003 0.025±0.0003 ns
22:6n−3 (DHA) 0.08±0.005 0.95±0.002 <0.001
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the retroperitoneal,gonadal,omental,interscapular,and subcuta-
neous, were dissected out and weighed. The mass of all adipose
depots were added to obtain a measure of total body fat mass.
At 6weeks of age, a sample from the retroperitoneal and sub-
cutaneous adipose depot was snap frozen in liquid nitrogen and
stored at −80˚C for subsequent determination of gene expression
by quantitative real time reverse transcription-PCR (qRT-PCR).
Blood samples were collected by cardiac puncture. The blood was
centrifuged at 3500rpm (800g), 4˚C for 15min. The plasma was
removed and stored at −20˚C for subsequent analyses of glucose,
insulin,andnon-esteriﬁedfreefattyacids(NEFA)concentrations.
Theremainingredbloodcellmasswasthenpreparedforfattyacid
analysis of red blood cell phospholipids as previously described
(Makrides et al., 1995).
LIPID EXTRACTION
All solvents used in this study were analytical grade and were pur-
chased from Ajax Finechem Pty Ltd (Auckland, New Zealand)
or Chem-Supply (SA, Australia). Other chemicals and reagents
were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless
speciﬁed otherwise. The total lipid concentration of the plasma
was determined following the protocol of Bligh and Dyer (1959)
using chloroform–methanol (2:1, v/v). The phospholipids were
separated from total lipid extracts by thin layer chromatography
(TLC) on silica gel plates (Silica gel 60H; Merck, Darmstadt, Ger-
many).Alipidclassstandard18–5(NU-CHEKPrep;Elysian,MN,
USA) was run on the plates for lipid identiﬁcation. The mobile
phase for TLC was petroleum spirit/acetone (3:1, v/v). The TLC
platesweresprayedwithﬂuorescein5-isothiocyanateinmethanol,
and the lipid classes present were visualized under UV light. The
phospholipid bands located at the bottom of TLC plate were
transferred into a vial containing 1% sulphuric acid (H2SO4)
in methanol. All solvents used for extraction and separation
contained 0.005% (w/v) of the antioxidant, butylated hydroxyl
toluene (BHT).
FATTY ACID METHYLATION AND GAS CHROMATOGRAPHIC ANALYSIS
OF FAME
All lipids and phospholipids were transesteriﬁed with 1% H2SO4
in methanol at 70˚C for 3h. After the samples were cooled, the
resulting fatty acid methyl esters (FAME) were extracted with n-
heptaneandtransferredintovialscontainingascoopofanhydrous
sodium sulfate (Na2SO4).
Fatty acid methyl esters were separated and quantiﬁed by gas
chromatography (GC) (Hewlett-Packard 6890; Palo Alto, CA,
USA) equipped with a capillary column (50m×0.32mm id)
coated with 0.25μm ﬁlm thickness silica (BPX-70; SGC Pty Ltd,
VIC,Australia),andaﬂameionizationdetector(FID).Theinjector
temperature was set at 250˚C and the FID temperature at 300˚C.
The oven temperature at injection was initially set at 140˚C and
wasprogrammedtoincreaseto220˚Catarateof5˚C/min.Helium
gaswasutilizedasacarrierataﬂowrateof 35cm/sinthecolumn.
The identiﬁcation and quantiﬁcation of FAMEs were achieved by
comparingtheretentiontimesandpeakarea%valuesof unknown
samples to those of commercial lipid standards (NU-CHEK Prep;
Elysian, MN, USA) using the Hewlett-Packard Chemstation data
system. FAME standards for unique n−3 LCPUFAs 24:5 n−3 and
24:6 n−3 were purchased from Larodan Fine Chemicals (Malmö,
Sweden).
DETERMINATION OF HORMONE AND METABOLITE CONCENTRATIONS
Plasma concentrations of non-esteriﬁed fatty acids (NEFA) and
glucose were determined using Wako NEFA C kit (Wako Pure
Chemical Industries Ltd,Osaka,Japan) and Inﬁnity Glucose Hex-
okinase kit (Thermo Electron, Pittsburgh, PA, USA) respectively.
Assays and analyses were conducted using Konelab 20 (Thermo
Scientiﬁc, Vantaa, Finland) and the coefﬁcient of variation for
both assays was <5%. Insulin concentrations were measured by
radioimmunoassay with a Linco Rat Insulin Kit (Linco Research,
St. Charles, MO, USA). The inter- and intra-assay coefﬁcients of
variation were both <10%.
ISOLATION OF RNA FROM ADIPOSE TISSUE AND REVERSE
TRANSCRIPTION
RNA was isolated from ∼100mg retroperitoneal and subcuta-
neous adipose tissue from 6week male and female offspring using
Trizol reagent (Invitrogen Australia Pty Limited, Australia) and
chloroform. The RNA was puriﬁed using the RNeasy Mini Kit
(QIAGENPtyLtd-Australia,Doncaster,Australia).Thepurityand
concentration of RNA were determined using a spectrophotome-
ter measuring absorbance at 260 and 280nm and the integrity of
the RNA was determined using agarose gel electrophoresis. cDNA
was then synthesized using the puriﬁed RNA (∼2μg), Super-
script III Reverse Transcriptase (Invitrogen Australia Pty Limited,
Australia) and random hexamers.
QUANTITATIVE REAL TIME REVERSE TRANSCRIPTION-PCR
Quantitative real time PCR was conducted using SYBR Green
in an ABI Prism 7300 Sequence Detection System (PE Applied
Biosystems, Foster City, CA, USA). The expression of sterol regu-
latory element-binding protein 1 (SREBP1), fatty acid synthase
(FAS), glycerol 3-phosphate dehydrogenase (G3PDH), peroxi-
some proliferator-activated receptor gamma (PPARγ),leptin,and
β-actin was determined by qRT-PCR. The primers for all genes
have been previously validated and published (Muhlhausler et al.,
2010a). The β-actin primer set was purchased from Qiagen Pty
Ltd. (Doncaster, Australia). Each PCR reaction contained 5μl
2×SYBR Green master mix (PE Applied Biosystems, Foster City,
CA, USA), 1μl each of forward and reverse primers at a concen-
tration of 60–900nM, 2μl of molecular grade water and 1μlo f
50ng/μl dilution of cDNA stock template. Each reaction was con-
ducted in triplicate. Cycling conditions include 40 cycles of 95˚C
for 1min and 60˚C for 1min. At the end of each run, melt curve
analysiswasperformedtoverifyampliﬁcationof asingleproduct.
A quality control sample was included on each plate in order to
conﬁrm consistency of results between individual runs, and the
inter-plate coefﬁcient of variation was <5%.
The abundance of each mRNA transcript was measured and
expression relative to that of β-actin was calculated using Q-gene
qRT-PCR analysis software. This software provides a quantitative
measureof therelativeabundanceof aspeciﬁctranscriptindiffer-
ent tissues by the comparative threshold cycle (Ct) method which
takes into account any differences in the ampliﬁcation efﬁcien-
cies of the target and reference genes. The Ct value was taken as
theloweststatisticallysigniﬁcant(>10SDincreaseinﬂuorescence
above the background signal in an ampliﬁcation reaction.
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STATISTICAL ANALYSIS
Dataarepresentedasmean±SEM.Theeffectof maternalomega-
3 supplementation during pregnancy and lactation on maternal
body weight at the end of lactation, maternal body fat mass
and maternal fatty acid, hormone, and metabolite concentrations
was analyzed by Student’s unpaired t-test. The effect of mater-
nal omega-3 supplementation on birth outcomes and fatty acid
composition of erythrocytes in 3- and 6-week offspring were sim-
ilarly examined. The effect of maternal omega-3 supplementation
on maternal weight change during pregnancy and lactation, and
postnatal weight gain in male and female offspring was deter-
mined using an ANOVA with repeated measures. The effect of
maternalomega-3supplementationandpupsexonhormoneand
metabolite concentrations, body fat mass, and adipocyte genes in
the offspring was determined using a two-way ANOVA. Where
the ANOVA identiﬁed a signiﬁcant interaction between sex and
maternal treatment, the effect of omega-3 supplementation was
analyzed separately in male and female offspring. Litter size was
included as a covariate in all analyses,and only one pup from each
litter was included for each measurement and time-point.All data
weretestedtoconﬁrmnormalityof distributionandrelationships
between variables were assessed using simple linear regression.
A P value of <0.05 was considered to be statistically signiﬁcant in
all analyses.
RESULTS
THE EFFECT OF MATERNAL OMEGA-3 SUPPLEMENTATION ON
MATERNAL CHARACTERISTICS DURING PREGNANCY AND LACTATION
There was no difference in omega-3 LCPUFA content of mater-
nal erythrocytes of rats assigned to the control and omega-3
DHA groups prior to being fed the experimental diets (Control,
6.01±0.09%; Omega-3, 6.40±0.33%). At the end of lactation,
DHA, EPA, and total omega-3 LCPUFA contents of maternal
erythrocytes were signiﬁcantly higher in the omega-3 supple-
mented dams compared to Controls (Table 2). There was no
effect of maternal omega-3 supplementation on omega-6 fatty
acid concentrations (Table 2).
Table 2 | Maternal erythrocyte phospholipid fatty acid composition
expressed as a percentage of total fatty acids and glucose, insulin,
and NEFA concentrations at the end of lactation in Control and
Omega-3 dams.
Control (n =10) Omega-3 (n =11) P value
EPA (%) 0.54±0.04 0.67±0.03 0.03
DHA (%) 2.30±0.11 3.68±0.22 <0.001
Total n−3 LCPUFA (%) 3.81±0.09 5.42±0.26 <0.001
LA (%) 7 .49±0.31 6.92±0.24 ns
AA (%) 19.654±0.61 18.44±0.87 ns
Glucose (mmol/l) 3.58±0.28 3.31±0.23 ns
Insulin (ng/ml) 1.12±0.19 1.10±0.16 ns
NEFA (mEq/l) 0.82±0.17 0.55±0.11 0.03
All values expressed as mean±SEM. Differences between the Omega-3 and
Control groups were determined using a Student’s unpaired t-test. P<0.05 was
considered statistically signiﬁcant.
There was no difference in the weight of the mothers before
mating (i.e., prior to allocation to the Control or Omega-3
diet; Control, 327.4±16.7g; Omega-3, 335.7±10.6g). There
was no effect of maternal omega-3 supplementation on mater-
nal weight gain during pregnancy (Control, 106.7±10.4g;
Omega-3, 103.5±14.9g) or weight loss after delivery (Control,
−75.5±9.6g;Omega-3,−79.7±12.0g),and there was no differ-
ence in maternal body weight at the end of lactation between the
Control and Omega-3 groups (Control, 340.6±10.9g; Omega-3,
354.1±4.9g).
At the end of lactation, the Omega-3 dams had a higher
total subcutaneous fat mass (Control, 1.06±0.18g; Omega-3,
3.12±0.84g,P<0.05)andalsotended(P<0.06)tohaveahigher
subcutaneous fat mass as a percentage of body weight (Control,
0.31±0.05%; Omega-3, 0.89±0.02%). There was no difference,
however, in the total or relative weight of any other major fat
depotsortotalpercentagebodyfat(percentbodyfatmass:Control,
4.8±0.4%; Omega-3,5.4±0.4%).
There was no difference in maternal glucose or insulin levels
between the Control and Omega-3 dams; however plasma NEFA
concentrationsattheendoflactationwerelowerinOmega-3dams
(Table 2). Maternal omega-3 intake had no effect on food intake
during either pregnancy (Control, 10.62±1.92g/day; Omega-
3, 14.94±4.8g/day) or lactation (Control, 15.78±4.89g/day;
Omega-3,12.5±3.6g/day).
PREGNANCY AND BIRTH OUTCOMES
There was no effect of maternal omega-3 supplementation
on length of gestation (Control, 22.3±0.5days; Omega-3,
23.3±0.6days), litter size (Control, 9.1±1.4 pups; Omega-3,
6.7±0.8 pups) or mean pup birth weight (Control,6.27±0.24g;
Omega-3, 6.94±0.41g). There were equal number of litters with
dead pups in each treatment group (Control, n =2 litters, DHA,
n =3 litters), and there was an average of two dead pups in each
of these litters. All pups that were not dead at birth survived until
weaning.
THE EFFECT OF MATERNAL OMEGA-3 SUPPLEMENTATION ON
OFFSPRING CHARACTERISTICS: FATTY ACID STATUS AND HORMONE
AND METABOLITE CONCENTRATIONS
The offspring of omega-3 supplemented dams had signiﬁcantly
higher concentrations of DHA, EPA, and total omega-3 LCPUFA
in their erythrocyte phospholipids at both 3 and 6weeks of age
(Table 3).
There was no effect of maternal omega-3 supplementation
or offspring sex on plasma insulin concentrations at either 3 or
6weeks of age (Table 4). There was also no effect of maternal
omega-3 supplementation on glucose concentrations at 3weeks
of age in either male or female offspring; however at 6weeks of
age, plasma glucose concentrations were lower in female Omega-
3 offspring compared to their Control counterparts (Table 4).
There was no effect of maternal omega-3 supplementation on
plasma glucose concentrations in 6week male offspring (Table 4).
At 3weeks, but not 6weeks, of age, plasma NEFA concentrations
were lower in Omega-3 offspring compared to Control offspring
in both males and females (Table 4).
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Table 3 | Erythrocyte phospholipid fatty acid composition expressed
as a percentage of total fatty acids at 3 and 6weeks of age in
offspring of Control and Omega-3 dams.
3Week offspring Control (n =14) Omega-3 (n =18) P value
EPA (%) 0.32±0.03 0.39±0.02 0.05
DHA (%) 4.53±0.27 7 .08±0.21 <0.001
Total n−3 LCPUFA (%) 6.67±0.33 9.39±0.28 <0.001
LA (%) 7 .16±0.88 6.50±0.08 ns
AA (%) 19.54±0.31 18.73±0.37 ns
6Week offspring Control (n =14) Omega-3 (n =16) P value
EPA (%) 0.28±0.04 0.43±0.02 <0.001
DHA (%) 3.19±0.12 4.08±0.11 <0.001
Total n−3 LCPUFA (%) 4.87±0.28 6.49±0.13 <0.001
LA (%) 8.57±0.30 8.94±0.22 ns
AA (%) 17 .73±0.54 18.85±0.32 ns
All values expressed as mean±SEM. Differences between the Omega-3 and
Control groups were determined using a Student’s unpaired t-test. P<0.05 was
considered statistically signiﬁcant.
Table 4 | Plasma glucose, insulin, and NEFA concentrations at 3 and
6weeks of age in offspring of Control and Omega-3 dams.
Male Female
3Week
offspring
Control
(n =7)
Omega-3
(n =9)
Control
(n =7)
Omega-3
(n =9)
Glucose (mmol/l) 4.12±0.19 3.36±0.17 3.66±0.28 3.65±0.17
Insulin (ng/ml) 0.57±0.06 0.95±0.20 0.75±0.18 1.10±0.16
NEFA (mEq/l) 0.61±0.06 0.43±0.04* 0.57±0.08 0.49±0.06*
6Week
offspring
Control
(n =9)
Omega-3
(n =8)
Control
(n =9)
Omega-3
(n =9)
Glucose (mmol/l) 3.69±0.39 4.03±0.38 3.42±0.24 2.71±0.10*
Insulin (ng/ml) 1.49±0.15 1.80±0.47 1.58±0.29 1.38±0.16
NEFA (mEq/l) 0.53±0.10 0.41±0.07 0.44±0.09 0.58±0.21
All values expressed as mean±SEM.The effect of Omega-3 treatment and sex
was determined using a two-way ANOVA. Where the ANOVA revealed a signiﬁ-
cantinteractionbetweentreatmentandsex,differencesbetweentheControland
Omega-3 groups were analyzed separately in male and female offspring using a
Students’ unpaired t-test. *denotes P<0.05 compared to Control offspring.
POSTNATAL GROWTH
There was no effect of maternal omega-3 supplementation on
weight gain of the pups between birth and weaning (Figure 1).
There was no effect of maternal omega-3 supplementation on
weight gain between weaning and 6weeks of age in either males
or females (Male: Control, 144.4±8.8g; Omega-3, 138.2±9.9g;
Female: Control, 106.8±7.9g; Omega-3, 98.0±4.8g). Body
weight,length,and abdominal circumference at weaning (3weeks
of age) and 6weeks were not different between the control and
Omega-3 offspring in either males or females (Table 5).
FIGURE 1 |Weight gain from birth to weaning in Control (open circles)
and Omega-3 (closed circles) offspring.The effect of Omega-3 treatment
on weight gain from birth to weaning was assessed by a one-way ANOVA
with repeated measures. Data from male and female offspring combined.
There was no effect of maternal omega-3 supplementation on weight gain
of the offspring from birth until weaning.
BODY COMPOSITION
There was no effect of maternal omega-3 supplementation on
the total or relative weight of any of the major visceral or sub-
cutaneous fat depots at 3weeks of age in either male or female
offspring (Table 5).
At 6weeks of age, total percentage body fat was higher in
Omega-3 offspring compared to Controls independent of sex
(F =6.18, P<0.01, Figure 2A). This appeared to be the result
of an increased accumulation of subcutaneous adipose tissue; the
subcutaneous fat mass as a percentage of body weight was greater
in male and female Omega-3 offspring compared to Controls
(F =5.62, P<0.03; Figure 2B), but there was no effect of mater-
nal omega-3 supplementation on the relative weight of the major
visceral fat depots, the omental, retroperitoneal, interscapular or
gonadal fat depots (Table 5).
EXPRESSION OF ADIPOGENIC AND LIPOGENIC GENES IN VISCERAL
AND SUBCUTANEOUS ADIPOSE TISSUE IN OFFSPRING AT
6WEEKS OF AGE
There was no effect of maternal omega-3 supplementation on the
expressionof PPARγ,FAS,SREBP-1c,G3PDH,orleptinmRNAin
retroperitoneal or subcutaneous adipose tissue in either male or
female offspring (Table 6). FAS mRNA expression in retroperi-
toneal adipose tissue tended (P=0.06) to be reduced in the
omega-3 female offspring compared to Controls.
When data from Omega-3 and Control offspring were com-
bined,there was a positive relationship between SREBP-1c mRNA
expression in retroperitoneal adipose tissue and erythrocyte EPA
concentrationsintheoffspring(r =0.45,P<0.05).Therewereno
relationships, however, between the expression of any adipogene-
sisandlipogenesis-relatedgenesandeitherDHAortotalomega-3
LCPUFA content of erythrocytes.
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Table 5 | Pup body weight, size, and percentage fat mass at 3 and 6weeks of age in offspring of Control and Omega-3 dams.
Male Female
3Week offspring Control (n =10) Omega-3 (n =11) Control (n =10) Omega-3 (n =11)
Body weight (g) 54.1±4.56 58.41±3.29 49.47±4.29 53.60±2.48
Body length (cm) 14.13±0.45 14.21±0.30 13.47±0.39 13.9±0.30
Abdominal circumference (cm) 10.25±0.30 11.17±0.39 10.43±0.42 10.94±0.44
Gonadal fat mass (%) 1.73±0.29 1.61±0.29 1.67±0.38 1.70±0.36
Retroperitoneal fat mass (%) 0.86±0.10 0.78±0.08 0.78±0.12 1.10±0.19
Omental fat mass (%) 0.56±0.60 0.52±0.03 0.55±0.03 0.52±0.04
Interscapular fat mass (%) 0.96±0.12 0.83±0.06 0.99±0.12 0.89±0.15
Subcutaneous fat mass (%) 2.63±0.25 2.91±0.65 2.71±0.24 3.16±0.42
Total fat mass (%) 6.81±0.66 6.66±0.98 5.30±0.11 6.70±0.83
6Week offspring Control (n =10) Omega-3 (n =10) Control (n =10) Omega-3 (n =10)
Body weight (g) 195.4±9.74 197 .8±10.12 156.3±8.18 153.7±5.21
Body length (cm) 21.78±0.22 21.30±0.51 19.31±0.20 20.01±0.26
Abdominal circumference (cm) 16.38±0.36 16.18±0.54 15.70±0.65 15.18±0.27
Interscapular fat mass (%) 0.33±0.02 0.38±0.08 0.39±0.05 0.52±0.06
Gonadal fat mass (%) 1.63±0.13 1.40±0.10 1.04±0.20 1.50±0.21
Retroperitoneal fat mass (%) 0.77±0.11 0.80±0.11 0.58±0.06 0.73±0.03
Omental fat mass (%) 0.58±0.04 0.56±0.03 0.59±0.04 0.59±0.03
All values expressed as mean±SEM.The effect of Omega-3 treatment and sex was determined using a two-way ANOVA.
DISCUSSION
We have shown that maternal omega-3 supplementation during
pregnancy and lactation was without effect on body weight or fat
mass of offspring at weaning, and was associated with a signif-
icant increase in percentage body fat at 6weeks of age in both
males and females when offspring were weaned onto a standard
ratfeedwhichwasnotsupplementedwithomega-3LCPUFA.This
increase in fat mass appeared to be restricted to subcutaneous
depots, and there was no effect of maternal omega-3 supplemen-
tation on the relative mass of visceral fat, suggesting a differential
susceptibility of distinct fat depots to the effects of perinatal
omega-3 LCPUFA supplementation. Interestingly, there was no
effect of maternal omega-3 supplementation on the expression of
any of the key adipogenic or lipogenic genes in the subcutaneous
depot,suggesting that the increased lipid accumulation is likely to
bedrivenbyamechanismotherthantheupregulationoflipogenic
gene transcription.
OMEGA-3 SUPPLEMENTATION DID NOT ADVERSELY AFFECT
PREGNANCY OUTCOME
We found that maternal omega-3 supplementation during preg-
nancy,atadoseequivalenttothatusedinhumanstudies(Makrides
et al., 2010), did not affect maternal body weight during preg-
nancy or lactation. The increased subcutaneous fat mass and
lower plasma NEFA concentrations at the end of lactation in
dams supplemented with omega-3 LCPUFA, however, suggest
that the increased intake of omega-3 LPCUFA resulted either in
an increased fat deposition or reduced mobilization of body fat
storesduringpregnancy.Therewasadeclineinomega-3LCPUFA
content of maternal erythrocytes during pregnancy and lactation
inthecontrolgroup,whichimpliesthatthecontroldietwasunable
tomeettheomega-3LCPUFArequirementsof pregnancyandlac-
tation, and that it was necessary for the Control dams to mobilize
maternal fat stores in order to meet their increased omega-3 LCP-
UFA requirements. The decline in omega-3 LCPUFA content was
blunted in the omega-3 dams, suggesting that requirements were
met to a large extent by the maternal diet. It is also possible that
theincreasedintakeof omega-3fattyacidsattenuatedthedecrease
in insulin sensitivity in peripheral tissues, including adipose tis-
sue, which is normally associated with pregnancy, since previous
studies have reported that increased intake of omega-3 fatty acids
is associated with enhanced peripheral insulin sensitivity in adult
humans and rodents (Semple et al., 2006). To our knowledge,
this is the ﬁrst study to report the impact of omega-3 supple-
mentation in pregnancy on fat mass in the mother, and it will
be important to determine whether this same effect is also seen
in humans, particularly given the increasing number of pregnan-
cies which are complicated by maternal overweight and obesity
(Catalano, 2007).
In agreement with clinical data from human pregnancies
(Makrides et al., 2006, 2010), and previous studies in animals
(Korotkova et al., 2002), we found no effect of maternal omega-
3 supplementation on pregnancy outcomes including number of
offspring and the proportion of males and females. Unlike clinical
studies, which have reported that maternal omega-3 supplemen-
tation during pregnancy is associated with a ∼2.6day (∼1%)
increase in gestation length and small but signiﬁcant increase in
b i r t hw e i g h to f∼47g (∼1.3% of average birth weight; Makrides
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FIGURE2|( A )PercentageTotal body fat mass and (B) Percentage
subcutaneous fat mass in male and female Control (open histograms) and
Omega-3 (closed histograms) offspring at 6weeks of age.The effect of sex
and treatment on body fat mass were determined by a two-way ANOVA.
Asterisks indicate a signiﬁcant main effect of maternal omega-3
supplementation during pregnancy and lactation (P<0.05).
et al.,2006),we found no effect of maternal omega-3 supplemen-
tation on gestation length or birth weight. It is likely, however,
that the relatively short gestation length of the rodent (∼21days)
compared to the human and the lower number of animals com-
pared to the number of infants in human clinical studies would
have made it very difﬁcult to detect such a modest increase in
gestation length (1% of a rodent gestation would be 0.21days).
Similarly, the increased birth weight in human infants is thought
to be a result of the modest increase in gestation length, and it
would be unlikely that such a small increase would be detectable
in a rodent model. Our ﬁndings are also in agreement with those
of previousrodentstudiesof maternalomega-3supplementation,
which also found no effects on birth weight (gestation length not
reported; Korotkova et al.,2002; Ibrahim et al.,2009). Overall,the
data from our study support previous ﬁndings that there are no
signiﬁcant adverse effects on the mother or on neonatal outcomes
associated with maternal omega-3 supplementation in humans
(Makrides et al., 2006,2010).
It has been demonstrated in previous studies that the level of
EPA and DHA in the breast milk is directly related to maternal
intake (Makrides et al., 1996), and this appeared to be the case in
the present study since the omega-3 pups had signiﬁcantly higher
EPA, DHA, and total omega-3 LCPUFA concentrations in their
erythrocyte phospholipids at weaning compared to the Control
group. Importantly, the elevated EPA, DHA, and total omega-3
LCPUFA concentration in erythrocyte phospholipids persisted at
6weeks of age, at which time all offspring (in both control and
omega-3 treatment groups) had been consuming a standard rat
chow (not supplemented with omega-3 LCPUFA) since weaning.
It therefore appears that fatty acids incorporated into erythrocyte
phospholipids before or during the suckling period are retained
after weaning and therefore have the potential to have more pro-
longed biological effects. This is perhaps not unexpected, since it
hasbeenshownthatittakesabout2–3weeksforchangesindietary
fat composition to result in signiﬁcant alterations in erythrocyte
fatty acid composition (Lands et al., 1990,1992).
Apart from the clear alterations in fatty acid status of the
omega-3 offspring at weaning there appeared to be little effect
of maternal omega-3 supplementation on growth or fat deposi-
tion during the suckling period, and there were no differences in
either visceral or subcutaneous fat mass between the control and
omega-3 offspring at weaning. The lack of effect of an increased
omega-3 supply in early infancy on postnatal growth is consistent
with data in term infants, where there is little evidence that an
increased supply of EPA and DHA in either breast milk or for-
mula during the immediate postnatal period is associated with an
altered weight gain in early infancy (Makrides et al., 1999, 2005).
The lower plasma NEFA concentrations in both male and female
omega-3 offspring at weaning, however, suggests that there may
have been an increased uptake of fatty acids into adipose tissue at
the end of weaning, although further studies are required to test
this hypothesis directly.
Whilsttherewasnodifferenceinbodyweightat6weeksof age,
wefoundthatpercentagebodyfatmasswassigniﬁcantlyincreased
in both male and female omega-3 offspring. This suggests that,
contrary to our hypothesis, an increased supply of omega-3 LCP-
UFA during the major period of fat development in the rodent
augmented fat accumulation and/or restricted growth of lean
mass in early postnatal life. This is unexpected, given the pre-
vious data linking increased omega-3 LCPUFA with reduced fat
differentiation and accumulation in adult rodents and in vitro
studies(Massieraetal.,2003;Masdenetal.,2005)andinoffspring
supplied with a high omega-3 diet in the post-weaning period
(Massiera et al., 2003; Wyrwoll et al., 2006; Ibrahim et al., 2009).
It is also at odds with the results of the only other study to date
whichhasdeterminedtheeffectofexposuretoanincreasedsupply
of omega-3 LCPUFA during the perinatal period alone on body
fatmassintheoffspringlaterinlife(Korotkovaetal.,2002).How-
ever, this previous study only determined fat mass and adipocyte
cell size in offspring at 1 and 3weeks of age, and may therefore
not have detected increases in fat mass which emerged later in
postnatal life. With the exception of the study by Wyrwoll et al.
(2006),which assessed percentage total body fat using Dual X-ray
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Table 6 | Expression of adipocyte genes in retroperitoneal and subcutaneous adipose tissue at 6weeks of age in offspring of Control and
Omega-3 dams (normalized to β-actin).
Male Female
Control (n =10) Omega-3 (n =10) Control (n =10) Omega-3 (n =10)
RETROPERITONEAL
SREBP-1c mRNA (×1000) 0.9±0.02 1.4±0.3 1.7±0.4 1.8±0.5
PPARγ mRNA 0.0143±0.003 0.0161± 0.003 0.0141±0.003 0.0136±0.003
FAS mRNA 0.131±0.058 0.152±0.039 0.567±0.085# 0.316±0.084#†
G3PDH mRNA 0.099±0.03 0.253±0.08 0.343±0.056 0.233±0.065
Leptin mRNA 0.0153±0.006 0.0122±0.005 0.0071±0.002 0.0068±0.002
SUBCUTANEOUS
SREBP-1c mRNA 0.0087±0.0030 0.0075±0.0006 0.0087±0.003 0.0130±0.005
PPARγ mRNA (×1000) 0.82±0.03 0.67± 0.02 1.7±0.7 0.7±0.3
FAS mRNA 0.251±0.060 0.256±0.130 0.353±0.170 0.104±0.047
G3PDH mRNA 0.220±0.11 0.221±0.089 0.363±0.180 0.105±0.046
Leptin mRNA 0.0028±0.001 0.0024±0.002 0.0024±0.001 0.0021±0.001
All values expressed as mean±SEM. The effect of Omega-3 treatment and sex was determined using a two-way ANOVA.
#denotes P<0.05 compared to male
offspring;
†denotes P=0.06 compared to Control females.
Absorptiometry, existing rodent studies have not included mea-
sures of subcutaneous fat mass, and may therefore have failed to
pick up on differences in fat mass conﬁned largely to this adipose
depot.
We found no effect of maternal omega-3 supplementation on
the expression of adipogenic and lipogenic genes in either the
retroperitonealorsubcutaneousfatdepotsat6weeksofage,which
impliesthattheincreaseinsubcutaneousfataccumulationwasthe
result of a mechanism other than the upregulation of lipogenic
geneexpression.ItisalsoclearthatDHAdidnotsuppressSREBP-
1c expression in fat depots during the early postnatal period in
the same way that it has been reported in adult rodents (Ailhaud
etal.,1992).Theobviousdifferencesintheeffectsofomega-3LCP-
UFA supplementation between adults and neonates suggest that
it may not be appropriate to extrapolate data obtained in mature
adipocytes to those for developing adipose cells.
So, how might an increased availability of omega-3 LCPUFA
augment fat deposition in early life? One possibility may be
that the increases in the availability of omega-3 LCPUFA leads
to increased activation of PPARγ in developing adipose depots,
thereby promoting fat cell differentiation (Soret et al., 1999) and
precocial lipid accumulation in developing adipocytes (Hutley
et al., 2003), and increasing peripheral insulin sensitivity (Sem-
ple et al., 2006). Omega-3 LCPUFA have been shown to act as
PPARγ agonists in vivo (Deckelbaum et al., 2006; Neschen et al.,
2006) and chronic treatment with synthetic PPARγ agonists is
associated with increases in subcutaneous, but not visceral, fat
massinadults(Smithetal.,2005;Buckingham and Hanna,2008).
Thisisalsosupportedbyepigeneticstudieswhichhaveshownthat
omega-3 LCPUFA inhibit the activity of the H3K27 methyltrans-
ferase, Ezh2, in cancer cells (Dimri et al., 2010). Since Ezh2 has
been shown to directly repress Wnt/β-catenin signaling (Wang
et al., 2010) and Wnt/β-catenin signaling inhibits adipogenesis,
reductions in Ehz2 activity as a result of omega-3 LCPUFA sup-
plementation would be expected to facilitate adipogenesis. The
abilityof omega-3LCPUFAsupplementationtoinduceepigenetic
changesduringdevelopmentisclearlyanimportantareaforfuture
investigation.
CONCLUSION
Although there has been much speculation about the poten-
tial for maternal omega-3 LCPUFA supplementation to limit fat
accumulation and improve long-term metabolic health in the off-
spring (Ailhaud et al., 2006; Hauner et al., 2009; Muhlhausler
et al., 2010a), there is still limited evidence which supports this
hypothesis. In the present study, we have demonstrated that
maternal omega-3 supplementation during pregnancy and lac-
tation in a rodent model resulted in increased fat accumulation
in both male and female offspring in early postnatal life. These
data, together with evidence from recent clinical studies (Lau-
ritzen et al., 2005; Asserhoj et al., 2009), suggest that the effect of
omega-3 LCPUFA on pre-adipocytes and developing fat depots is
likely to be distinct from their effects on mature adipose depots
and cells in culture, and that there is a need to exercise cau-
tion when extrapolating results from adult and in vitro studies
to effects during development in vivo. It is important to note
that the increase in fat mass is restricted to subcutaneous depots,
whereas the majority of adverse metabolic effects of obesity are
the result of excess visceral adipose tissue (Smith et al., 2001),
and therefore the metabolic health of the offspring may not nec-
essarily be adversely affected. It is clear that further studies are
required in order to more fully elucidate the mechanisms of
action of omega-3 LCPUFA on fat depots, including epigenetic
effects, and to determine the effects of maternal omega-3 supple-
mentation on metabolic health of the offspring throughout the
life-course
ACKNOWLEDGMENTS
This work was funded by a grant from the Division of Health Sci-
ences, University of South Australia and a Channel 7 Children’s
Frontiers in Genetics | Epigenomics July 2011 | Volume 2 | Article 48 | 8Muhlhausler et al. Prenatal omega-3 and fat deposition
Health Research Foundation grant to Beverly Sara Muhlhausler.
Beverly Sara Muhlhausler is supported by a Career Development
Award from the National Health and Medical Research Coun-
cil of Australia (NHMRC). Robert A. Gibson is supported by
a Senior Research Fellowship from the NHRMC. The authors
wish to acknowledge the assistance of Mr. David Phuong and
Ms. Lauren Astill with assistance with animal protocols and John
Carragher for assistance in editing the manuscript.
REFERENCES
Ailhaud, G., Grimaldi, P., and Negrel,
R. (1992). Cellular and molecular
aspects of adipose tissue develop-
ment. A n n u .R e v .N u t r .12, 207–233.
Ailhaud, G., Massiera, F., Weill, P.,
Legrand, P., Alessandri, J. M.,
and Guesnet, P. (2006). Temporal
changes in dietary fats: role of n-6
polyunsaturated fatty acids in exces-
sive adipose tissue development and
relationship to obesity. Prog. Lipid
Res. 45, 203–236.
Armitage, J. A., Khan, I. Y., Taylor, P.
D., Nathanielsz, P. W., and Poston,
L. (2004). Developmental program-
ming of the metabolic syndrome
by maternal nutritional imbalance:
how strong is the evidence from
experimental models in mammals?
J. Physiol. (Lond.) 561, 355–377.
Asserhoj, M., Nehammer, S.,
Matthiessen, J., Michaelsen, K.
F., and Lauritzen, L. (2009). Mater-
nal ﬁsh oil supplementation during
lactation may adversely affect long-
term blood pressure, energy intake,
and physical activity of 7-year-old
boys. J. Nutr. 139, 298–304.
Bligh, E. G., and Dyer, W. J. (1959).
A rapid method of total lipid
extraction and puriﬁcation. Can. J.
Biochem. Physiol. 37, 911–917.
Buckingham, R. E., and Hanna, A.
(2008). Thiazolidinedione insulin
sensitizers and the heart: a tale of
two organs? Diabetes Obes. Metab.
10, 312–328.
Catalano, P. M. (2007). Management
of obesity in pregnancy. Obstet.
Gynecol. 109, 419–433.
Deckelbaum, R. J., Worgall, T. S., and
Seo, T. (2006). n-3 fatty acids and
gene expression. Am. J. Clin. Nutr.
83, 1520S–1525S.
Dimri, M., Bommi, P. V., Sahasrabud-
dhe, A. A., Khandekar, J. D.,
and Dimri, G. P. (2010). Dietary
omega-3polyunsaturatedfattyacids
suppress expression of EZH2 in
breastcancercells.Carcinogenesis 31,
489–495.
Hauner, H.,Vollhardt, C., Schneider, K.
T., Zimmermann, A., Schuster, T.,
andAmann-Gassner,U. (2009). The
impactofnutritionalfattyacidsdur-
ingpregnancyandlactationonearly
human adipose tissue development.
Rationale and design of the INFAT
study. Ann. Nutr. Metab. 54,97–103.
Hutley, L. J., Newell, F. M., Joyner, J.
M., Suchting, S. J., Herington, A.
C., Cameron, D. P., and Prins, J. B.
(2003). Effects of rosiglitazone and
linoleicacidonhumanpreadipocyte
differentiation. Eur. J. Clin. Invest.
33, 574–581.
Ibrahim, A., Null, G., Basak, S., and
Ehtesham, N. Z. (2009). Impact of
maternal dietary fatty acid compo-
sition on glucose and lipid metabo-
lism in male rat offspring aged 105
d. B r .J .N u t r .102, 233–241.
Kasser, T. R., Martin, R. J., and Allen,
C. E. (1981). Effect of gestational
alloxan diabetes and fasting on fetal
lipogenesis and lipid deposition in
pigs. Biol. Neonate 40, 105–112.
Korotkova, M., Gabrielsson, B., Lonn,
M., Hanson, L.-A., and Strandvik,
B. (2002). Leptin levels in rat off-
spring are modiﬁed by the ratio of
linoleic to {alpha}-linolenic acid in
the maternal diet. J. Lipid Res. 43,
1743–1749.
Lands, W. E., Libelt, B., Morris, A.,
Kramer,N. C.,Prewitt,T. E.,Bowen,
P., Schmeisser, D., Davidson, M.
H., and Burns, J. H. (1992). Main-
tenance of lower proportions of
(n - 6) eicosanoid precursors in
phospholipids of human plasma in
response to added dietary (n - 3)
fatty acids. Biochim. Biophys. Acta
1180, 147–162.
Lands, W. E., Morris, A., and Libelt,
B. (1990). Quantitative effects of
dietary polyunsaturated fats on the
composition of fatty acids in rat
tissues. Lipids 25, 506–516.
Lauritzen, L., Hoppe, C., Straarup, E.
M., and Michaelsen, K. F. (2005).
Maternal ﬁsh oil supplementation
in lactation and growth during the
ﬁrst 2.5 years of life. Pediatr. Res. 58,
235–242.
Makrides, M., Duley, L., and Olsen,
S. F. (2006). Marine oil, and other
prostaglandin precursor, supple-
mentation for pregnancy uncompli-
cated by pre-eclampsia or intrauter-
ine growth restriction. Cochrane
Database Syst. Rev. 3, 1–25.
Makrides, M., Gibson, R. A., McPhee,
A. J., Yelland, L., Quinlivan, J.,
Ryan, P., and Team, D. I. (2010).
Effect of DHA supplementation
during pregnancy on maternal
depression and neurodevelopment
of young children. JAMA 304,
1675–1683.
Makrides, M., Gibson, R. A., Udell, T.,
Ried, K., and the International, L.
I.(2005).Supplementationof infant
formula with long-chain polyunsat-
urated fatty acids does not inﬂuence
the growth of term infants. Am. J.
Clin. Nutr. 81, 1094–1101.
Makrides, M., Neumann, M. A., and
Gibson,R.A.(1996).Effectofmater-
nal docosahexaenoic acid (DHA)
supplementation on breast milk
composition. Eur. J. Clin. Nutr. 50,
352–357.
Makrides, M., Neumann, M. A., Sim-
mer, K., and Gibson, R. A. (1999).
Dietary long-chain polyunsaturated
fatty acids do not inﬂuence growth
of term infants: a randomized clini-
cal trial. Pediatrics 104, 468–475.
Makrides, M., Simmer, K., Neumann,
M., and Gibson, R. (1995). Changes
in the polyunsaturated fatty acids of
breast milk from mothers of full-
term infants over 30 wk of lactation.
Am. J. Clin. Nutr. 61, 1231–1233.
Masden, L., Koefoed Petersen, R., and
Kristiansen, K. (2005). Regulation
of adipocyte differentiation and
function by polyunsaturated fatty
acids. Biochim. Biophys. Acta 1740,
266–286.
Massiera, F., Guesnet, P., and Ailhaud,
G.(2006).Thecrucialroleof dietary
n-6 polyunsaturated fatty acids in
excessive adipose tissue develop-
ment:relationshiptochildhoodobe-
sity. Nestle Nutr. Workshop Ser. Pedi-
atr. Program. 57, 235–242.
Massiera, F., Saint-Marc, P., Seydoux, J.,
Murata,T.,Kobayashi,T.,Narumiya,
S., Guesnet, P., Amri, E.-Z., Negrel,
R., and Ailhaud, G. (2003). Arachi-
donic acid and prostacyclin signal-
ing promote adipose tissue develop-
ment: a human health concern? J.
Lipid Res. 44, 271–279.
McMillen, I. C., and Robinson, J. S.
(2005). Developmental origins of
themetabolicsyndrome:prediction,
plasticity, and programming. Phys-
iol. Rev. 85, 571–633.
Meyer,B.J.,Mann,N.J.,Lewis,J.L.,Mil-
ligan,G.C.,Sinclair,A.J.,andHowe,
P. R. (2003). Dietary intakes and
foodsourcesofomega-6andomega-
3 polyunsaturated fatty acids. Lipids
38, 391–398.
Muhlhausler,B.S.,Adam,C.L.,Findlay,
P. A., Dufﬁeld, J. A., and McMillen,
I. C. (2006). Increased maternal
nutrition alters development of the
appetite-regulating network in the
brain. FASEB J. 20, 1257–1259.
Muhlhausler, B. S., Cook-Johnson, R.,
James,M.,Miljkovic,D.,Duthoit,E.,
and Gibson, R. (2010a). Opposing
effectsofomega-3andomega-6long
chain polyunsaturated fatty acids on
the expression of lipogenic genes in
omentalandretroperitonealadipose
depots in the rat. J. Nutr. Metab. doi:
10.1155/2010/927836. [Epub ahead
of print].
Muhlhausler, B. S., Gibson, R. A.,
and Makrides, M. (2010b). Effect
of long-chain polyunsaturated fatty
acid supplementation during preg-
nancy or lactation on infant and
child body composition: a system-
atic review. Am. J. Clin. Nutr. 92,
857–863.
Muhlhausler, B. S., Dufﬁeld, J. A.,
and McMillen, I. C. (2007).
Increased maternal nutrition
stimulates peroxisome prolifera-
tor activated receptor-{gamma}
(PPAR{gamma}), adiponectin and
leptin mRNA expression in adipose
tissue before birth. Endocrinology
148, 878–885.
Neschen, S., Morino, K., Rossbacher,
J. r. C., Pongratz, R. L., Cline,
G. W., Sono, S., Gillum, M.,
and Shulman, G. I. (2006). Fish
oil regulates adiponectin secre-
tion by a peroxisome proliferatorâ
C“activated receptor-g dependent
mechanism in mice. Diabetes 55,
924–928.
Okuno, M., Kajiwara, K., Imai, S.,
Kobayashi, T., Honma, N., Maki,
T., Suruga, K., Goda, T., Takase,
S., Muto, Y., and Moriwaki, H.
(1997).Perillaoilpreventstheexces-
sive growth of visceral adipose tis-
sue in rats by down-regulating
adipocyte differentiation. J. Nutr.
127, 1752–1757.
Plagemann,A., Harder, T., Kohlhoff, R.,
Rhode, W., and Dorner, G. (1997).
Overweight and obesity in infants
of mothers with long-term insulin-
dependent diabetes or gestational
diabetes. Int. J. Obes. Relat. Metab.
Disord. 21, 451–456.
Raclot,T.,Groscolas,R.,Langin,D.,and
Ferre, P. (1997). Site-speciﬁc reg-
ulation of gene expression by n-3
polyunsaturated fatty acids in rat
whiteadiposetissues.J.LipidRes.38,
1963–1972.
Ruzickova, J., Rossmeisl, M., Prazak,
T., Flachs, P., Sponarova, J., Veck,
M., Tvrzicka, E., Bryhn, M., and
Kopecky, J. (2004). Omega-3 PUFA
of marine origin limit diet-induced
obesity in mice by reducing
www.frontiersin.org July 2011 | Volume 2 | Article 48 | 9Muhlhausler et al. Prenatal omega-3 and fat deposition
cellularity of adipose tissue. Lipids
39, 1177–1185.
Semple, R. K., Chatterjee, V. K. K., and
O’Rahilly, S. (2006). PPAR{gamma}
and human metabolic disease. J.
Clin. Invest. 116, 581–589.
Smith, S. R., de Jonge, L., Volaufova, J.,
Li,Y.,Xie,H.,andBray,G.A.(2005).
Effect of pioglitazone on body com-
position and energy expenditure: a
randomized controlled trial. Metab.
Clin. Exp. 54, 24–32.
Smith, S. R., Lovejoy, J. C., Green-
way, F., Ryan, D., deJonge, L.,
de la Bretonne, J., Volafova, J.,
and Bray, G. A. (2001). Contri-
butions of total body fat, abdom-
inal subcutaneous adipose tissue
compartments, and visceral adipose
tissue to the metabolic complica-
tionsof obesity.Metab.Clin.Exp.50,
425–435.
Soret, B., Lee, H. J., Finley, E., Lee, S. C.,
andVernon,R.G.(1999).Regulation
of differentiation of sheep subcuta-
neous and abdominal preadipocytes
in culture. J. Endocrinol. 161, 517–
524.
Wang, L., Jin, Q., Lee, J.-E., Su, I.-H.,
and Ge, K. (2010) Histone H3K27
methyltransferase Ezh2 represses
Wnt genes to facilitate adipogene-
sis. Proc. Natl. Acad. Sci. U.S.A. 107,
7317–7322.
World Health Organisation. (2006).
Fact Sheet: Obesity and Overwei-
ght. Available at: http://www.who.
int/mediacentre/factsheets/fs311/en/
print.html., World Health
Organisation.
Wyrwoll, C. S., Mark, P. J., Mori, T.
A., Puddey, I. B., and Waddell, B. J.
(2006). Prevention of programmed
hyperleptinemia and hypertension
by postnatal dietary {omega}-3
fatty acids. Endocrinology 147,
599–606.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 10 May 2011; accepted: 05 July
2011; published online: 21 July 2011.
Citation: Muhlhausler BS, Miljkovic D,
Fong L, Xian CJ, Duthoit E and Gibson
RA (2011) Maternal omega-3 supple-
mentation increases fat mass in male and
female rat offspring. Front. Gene. 2:48.
doi: 10.3389/fgene.2011.00048
This article was submitted to Frontiers in
Epigenomics, a specialty of Frontiers in
Genetics.
Copyright © 2011 Muhlhausler,
Miljkovic, Fong, Xian, Duthoit and
Gibson. This is an open-access article
subjecttoanon-exclusivelicensebetween
the authors and Frontiers Media SA,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are
credited and other Frontiers conditions
are complied with.
Frontiers in Genetics | Epigenomics July 2011 | Volume 2 | Article 48 | 10